2.要約四半期連結財務諸表及び主な注記
(1)要約四半期連結財政状態計算書
| | | (単位:百万円) |
| 前連結会計年度 (2024年12月31日) | | 当第3四半期連結会計期間 (2025年9月30日) |
資産 | | | |
非流動資産 | | | |
有形固定資産 | 5,696 | | 5,346 |
使用権資産 | 1,559 | | 1,810 |
のれん | 15,994 | | 15,071 |
無形資産 | 11,026 | | 11,694 |
持分法で会計処理されている投資 | 386 | | 350 |
繰延税金資産 | 2,234 | | 2,138 |
その他の金融資産 | 5,764 | | 4,957 |
その他の非流動資産 | 56 | | 73 |
非流動資産合計 | 42,720 | | 41,442 |
| | | |
流動資産 | | | |
棚卸資産 | 2,529 | | 3,811 |
営業債権及びその他の債権 | 6,236 | | 6,061 |
その他の金融資産 | 9,291 | | 7,662 |
その他の流動資産 | 1,050 | | 842 |
現金及び現金同等物 | 10,115 | | 22,777 |
流動資産合計 | 29,222 | | 41,155 |
資産合計 | 71,942 | | 82,597 |
| | | |
負債及び資本 | | | |
非流動負債 | | | |
借入金 | 1,200 | | 900 |
リース負債 | 735 | | 975 |
繰延税金負債 | 2,171 | | 2,141 |
その他の金融負債 | 15,454 | | 15,620 |
その他の非流動負債 | 203 | | 395 |
非流動負債合計 | 19,764 | | 20,032 |
| | | |
流動負債 | | | |
営業債務及びその他の債務 | 2,263 | | 1,982 |
借入金 | 4,575 | | 2,350 |
1年内返済予定の長期借入金 | 400 | | 400 |
リース負債 | 295 | | 348 |
未払法人所得税 | 2,611 | | 2,734 |
その他の金融負債 | 0 | | 2 |
その他の流動負債 | 2,318 | | 2,215 |
流動負債合計 | 12,464 | | 10,033 |
負債合計 | 32,229 | | 30,066 |
| | | |
資本 | | | |
資本金 | 13,276 | | 19,638 |
資本剰余金 | 6,626 | | 15,659 |
自己株式 | △15 | | △15 |
利益剰余金 | 9,888 | | 9,393 |
その他の資本の構成要素 | 6,669 | | 5,374 |
親会社の所有者に帰属する持分合計 | 36,446 | | 50,050 |
非支配持分 | 3,267 | | 2,481 |
資本合計 | 39,713 | | 52,531 |
資本及び負債の合計 | 71,942 | | 82,597 |
E0571221600株式会社ジーエヌアイグループGNI Group Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2025-01-012025-09-30Q32025-12-312024-01-012024-09-302024-12-311falsefalsefalse216002023-12-31jpigp_cor:TreasurySharesIFRSMember216002023-12-31jpigp_cor:RetainedEarningsIFRSMember216002023-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember216002023-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember216002023-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember216002023-12-31jpigp_cor:NonControllingInterestsIFRSMember216002024-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember216002024-12-31jpigp_cor:ShareCapitalIFRSMember216002024-12-31jpigp_cor:CapitalSurplusIFRSMember216002024-12-31jpigp_cor:TreasurySharesIFRSMember216002024-12-31jpigp_cor:RetainedEarningsIFRSMember216002023-12-31jpigp_cor:CapitalSurplusIFRSMember216002024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember216002024-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember216002024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember216002024-12-31jpigp_cor:NonControllingInterestsIFRSMember216002024-01-012024-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember216002024-01-012024-09-30jpigp_cor:ShareCapitalIFRSMember216002024-01-012024-09-30jpigp_cor:CapitalSurplusIFRSMember216002024-01-012024-09-30jpigp_cor:TreasurySharesIFRSMember216002024-01-012024-09-30jpigp_cor:RetainedEarningsIFRSMember216002024-01-012024-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember216002024-01-012024-09-30jpigp_cor:ShareAcquisitionRightsIFRSMember216002025-09-30jpigp_cor:TreasurySharesIFRSMember216002025-09-30jpigp_cor:RetainedEarningsIFRSMember216002025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember216002025-09-30jpigp_cor:ShareAcquisitionRightsIFRSMember216002025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember216002025-09-30jpigp_cor:NonControllingInterestsIFRSMember216002024-01-012024-09-30jpcrp_cor:ReportableSegmentsMember216002024-01-012024-09-30tse-qcediffr-21600:PharmaceuticalReportableSegmentMember216002024-01-012024-09-30tse-qcediffr-21600:MedicalDeviceReportableSegmentMember216002025-01-012025-09-30jpcrp_cor:ReportableSegmentsMember216002025-01-012025-09-30tse-qcediffr-21600:PharmaceuticalReportableSegmentMember216002025-01-012025-09-30tse-qcediffr-21600:MedicalDeviceReportableSegmentMember216002023-12-31216002024-12-31216002024-01-012024-09-30216002024-09-30216002025-01-012025-09-30216002025-09-30216002025-11-14216002023-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember216002023-12-31jpigp_cor:ShareCapitalIFRSMember216002024-09-30jpigp_cor:NonControllingInterestsIFRSMember216002025-01-012025-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember216002025-01-012025-09-30jpigp_cor:ShareCapitalIFRSMember216002025-01-012025-09-30jpigp_cor:CapitalSurplusIFRSMember216002025-01-012025-09-30jpigp_cor:TreasurySharesIFRSMember216002025-01-012025-09-30jpigp_cor:RetainedEarningsIFRSMember216002025-01-012025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember216002025-01-012025-09-30jpigp_cor:ShareAcquisitionRightsIFRSMember216002025-01-012025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember216002025-01-012025-09-30jpigp_cor:NonControllingInterestsIFRSMember216002025-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember216002025-09-30jpigp_cor:ShareCapitalIFRSMember216002025-09-30jpigp_cor:CapitalSurplusIFRSMember216002024-01-012024-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember216002024-01-012024-09-30jpigp_cor:NonControllingInterestsIFRSMember216002024-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember216002024-09-30jpigp_cor:ShareCapitalIFRSMember216002024-09-30jpigp_cor:CapitalSurplusIFRSMember216002024-09-30jpigp_cor:TreasurySharesIFRSMember216002024-09-30jpigp_cor:RetainedEarningsIFRSMember216002024-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember216002024-09-30jpigp_cor:ShareAcquisitionRightsIFRSMember216002024-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMemberiso4217:JPYxbrli:pureiso4217:JPYxbrli:shares